首页> 外文期刊>The Internet Journal of Oncology >Survival Rate Analysis Of Patients With Advanced Ovarian Cancer Treated According To Different Protocols
【24h】

Survival Rate Analysis Of Patients With Advanced Ovarian Cancer Treated According To Different Protocols

机译:不同方案治疗晚期卵巢癌患者的生存率分析

获取原文
           

摘要

PURPOSE: Certain indications point out that application of systemic chemotherapy prior to radical surgery can influence the length of remission period as well as overall survival. Aim of this paper is to analyse progression-free survival and overall survival rates of patients with advanced ovarian carcinoma primary treated according to different therapeutical procedures: by systemic chemotherapy after which underwent citoreductive surgery and those treated by radical surgery and received chemotherapy and to compare survival data.PATIENTS AND METHODS: This study included 168 patients with advanced ovarian carcinoma. Patients were divided in four groups. First group of patients underwent systemic chemotherapy prior to radical surgery. Patients of second and third group first had radical surgery followed by chemotherapy; after chemotherapy, patients from the second group underwent citoreductive surgery. Patients from the fourth group were treated with systemic chemotherapy only. Progression-free survival and overall survival rate were calculated according to Kaplan-Mayer method. Log Rang test was used to compare survival rates.RESULTS: The longest progression-free survival (28 months) and overall survival rate (43 months) was recorded for patients subjected to radical surgery after systemic chemotherapy. Their survival was significantly better (p<0.01) than survival of patients who first underwent radical surgery after which chemotherapy was applied and especially better than survival of patients who were administered chemotherapy only (p<0.0001) since their survival data was the worst (6 months progression-free and 14 months overall).CONCLUSION: Application of systemic chemotherapy prior to radical surgery has been proven efficient in treatment and survival of patients with advanced ovarian carcinoma. INTRODUCTION Possible survival assessment of ovarian carcinoma patients is very complex and requires analysis of a great number of factors which can influence survival. The most important factors are disease stadium, age and residual tumour after laparotomy, histopathological type and clinical stage of the disease [1]. Each of these factors influence patient survival in a certain way, аnd their analysis is a complex issue which is still a very frequent focus of interest of scientists around the world. Surgical cytoreduction is the key factor influencing survival of patients with advanced ovarian carcinoma. Nevertheless, it is not always possible to perform surgical cytoreduction due to numerous possible complications [2, 3]. This is why in recent years various references often include discussions about when radical surgery should be applied аnd when systemic chemotherapy should be used, i.e. which is the optimal moment for radical surgical treatment of patients with advanced ovarian carcinoma [4]. The role of systemic chemotherapy prior to radical surgery becomes even more important when taken into account that it facilitates subsequent performance of optimal radical cytoreduction, which is still the key factor influencing the survival data, coupled with the possibility of intraoperative intraperitoneal application of chemotherapy drugs which, according to the most recent research, treatment doubles survival length [5, 6]. OBJECTIVE To analyse progression-free survival and the overall survival rates of patients with advanced ovarian carcinoma treated according to different protocols: by systemic chemotherapy before radical surgery, by radical surgery after which received chemotherapy and cytoreductive surgery and to compare survival data. PATIENTS AND METHODS This study included 168 patients with advanced ovarian carcinoma who were treated and subjected to surgery in University Clinic for Obstetrics and Gynaecology “Narodni Front” in Belgrade in the period 2007-2010. The research was organized as a prospective study. Patients were divided in four groups. First group of patients underwent systemic chemotherapy prior to radical surge
机译:目的:某些迹象表明,在根治性手术之前应用全身化学疗法会影响缓解期的长短以及总体生存期。本文的目的是分析根据不同治疗方法接受原发性治疗的晚期卵巢癌患者的无进展生存期和总生存率:先行全身化疗后行化疗,然后行根治性手术并接受化疗,以比较生存率数据和方法:本研究包括168例晚期卵巢癌患者。将患者分为四组。第一组患者在接受根治性手术之前接受了全身化疗。第二和第三组患者首先进行了根治性手术,随后进行了化疗。化疗后,第二组患者进行了瓜叶性手术。第四组患者仅接受全身化疗。根据Kaplan-Mayer方法计算无进展生存期和总生存率。结果:系统化疗后接受根治性手术的患者的最长无进展生存期(28个月)和总生存期(43个月)被记录下来。他们的生存率比首次接受根治性手术后接受化疗的患者的生存率显着好(p <0.01),尤其是比仅接受化疗的患者的生存率(p <0.0001)更好,因为他们的生存数据最差(6结论:根治性手术前应用全身化疗已被证明可有效治疗晚期卵巢癌患者并提高其生存率。引言卵巢癌患者可能的生存评估非常复杂,需要分析许多可能影响生存的因素。最重要的因素是疾病场,开腹手术后的年龄和残留肿瘤,疾病的组织病理学类型和临床分期[1]。这些因素中的每一个都以某种方式影响患者的生存,而他们的分析是一个复杂的问题,仍然是世界各地科学家经常关注的焦点。外科细胞减少是影响晚期卵巢癌患者生存的关键因素。然而,由于许多可能的并发症[2,3],并不总是能够进行外科细胞减灭术。这就是为什么近年来各种参考文献经常讨论何时应进行根治性手术以及何时应应用全身化学疗法,即这是晚期卵巢癌患者进行根治性手术治疗的最佳时机[4]。如果考虑到全身化疗有助于促进最佳的根治性细胞减少的后续表现,那么全身性化疗在根治性手术之前的作用就显得尤为重要,这仍然是影响生存数据的关键因素,并且有可能在术中腹膜内应用化疗药物,根据最新研究,治疗可使生存期延长一倍[5,6]。目的分析按照不同方案治疗的晚期卵巢癌患者的无进展生存期和总生存率:在接受根治性手术前进行全身化疗,然后接受化疗和细胞减灭术后进行根治性手术,并比较生存数据。患者与方法这项研究纳入了168例晚期卵巢癌患者,这些患者在2007-2010年期间于贝尔格莱德大学妇产科诊所“ Narodni Front”接受了治疗并接受了手术。该研究是作为一项前瞻性研究而组织的。将患者分为四组。第一组患者在激增之前接受了全身化学疗法

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号